ArticleiScience2026
Breast cancer burden risk attribution and productivity loss in Chinese women aged 25 to 49.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer among Chinese women aged 25-49 years has substantial clinical and societal consequences. We integrated Global Burden of Disease (GBD) 2023 estimates for 1990-2023 with Global Cancer Observatory (GLOBOCAN) 2022, United Nations population projections, International Labour Organization labour-force participation, and World Bank indicators. Incident cases rose from 50,064 to 87,221, while the weighted death rate declined from 9.25 to 4.72 per 100,000. Demographic changes explained 63.0% of additional cases. In exploratory extreme gradient boosting (XGBoost) analyses interpreted with SHapley Additive exPlanations (SHAP), the fasting-plasma-glucose-related population attributable fraction (PAF) ranked first in several formulations but weakened after removing age and temporal structure; the selected high-body-mass-index (BMI) PAF series was constant at zero and unrankable. Potential mortality-related productivity loss was US$6.161 billion in 2023. Status-quo projections suggested increasing incidence through 2050 with very wide uncertainty, supporting surveillance and individual-level validation rather than immediate screening policy changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.